BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 31573049)

  • 21. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inherited Mutations in Women With Ovarian Carcinoma.
    Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
    JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations.
    Jara L; Morales S; de Mayo T; Gonzalez-Hormazabal P; Carrasco V; Godoy R
    Biol Res; 2017 Oct; 50(1):35. PubMed ID: 28985766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.
    Lilyquist J; LaDuca H; Polley E; Davis BT; Shimelis H; Hu C; Hart SN; Dolinsky JS; Couch FJ; Goldgar DE
    Gynecol Oncol; 2017 Nov; 147(2):375-380. PubMed ID: 28888541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline RAD51C mutations in ovarian cancer susceptibility.
    Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
    Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
    Brunsvold AN; Wung SF; Merkle CJ
    J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia.
    Mundhofir FE; Wulandari CE; Prajoko YW; Winarni TI
    Asian Pac J Cancer Prev; 2016; 17(3):1539-46. PubMed ID: 27039803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary Ovarian Cancer and Risk Reduction.
    Andrews L; Mutch DG
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():31-48. PubMed ID: 28254144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
    Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
    Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer.
    Narod SA; Boyd J
    Curr Opin Obstet Gynecol; 2002 Feb; 14(1):19-26. PubMed ID: 11801872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
    Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
    PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rare ATAD5 missense variants in breast and ovarian cancer patients.
    Maleva Kostovska I; Wang J; Bogdanova N; Schürmann P; Bhuju S; Geffers R; Dürst M; Liebrich C; Klapdor R; Christiansen H; Park-Simon TW; Hillemanns P; Plaseska-Karanfilska D; Dörk T
    Cancer Lett; 2016 Jun; 376(1):173-7. PubMed ID: 27045477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
    PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population analysis of microsatellite genotypes reveals a signature associated with ovarian cancer.
    Fonville NC; Vaksman Z; McIver LJ; Garner HR
    Oncotarget; 2015 May; 6(13):11407-20. PubMed ID: 25779658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hereditary ovarian cancer: beyond the usual suspects.
    Pennington KP; Swisher EM
    Gynecol Oncol; 2012 Feb; 124(2):347-53. PubMed ID: 22264603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer.
    Song H; Ramus SJ; Kjaer SK; Hogdall E; Dicioccio RA; Whittemore AS; McGuire V; Hogdall C; Jacobs IJ; Easton DF; Ponder BA; Dunning AM; Gayther SA; Pharoah PD
    PLoS One; 2007 Mar; 2(3):e268. PubMed ID: 17342202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.